JNJ26481585 is primarily investigated for its potential in cancer therapy, particularly as a histone deacetylase (HDAC) inhibitor. It is studied for its ability to modify gene expression by altering chromatin structure, which can lead to the suppression of tumor growth and induction of apoptosis in cancer cells. Research has focused on its application in treating various types of cancers, including hematological malignancies and solid tumors. Additionally, it is being explored in combination therapies to enhance the efficacy of other anticancer agents, potentially improving patient outcomes in resistant or aggressive cancers.